Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-1: Lybalvi in acute exacerbation of schizophrenia
NCT02634346Phase 3Completed
- Sponsor
- Alkermes
- Start
- Dec 2015
- Primary completion
- May 2017
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 4
01
Overview
A Phase 3 trial of olanzapine + samidorphan in schizophrenia, sponsored by Alkermes. Started Dec 2015; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02634346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634346.